Loss-of-function mutations have been described in several tumor types, including germline and somatic mutations in parathyroid cancer (Yu et al., 2015) and somatic mutations in solid papillary carcinoma (Alsadoun et al., 2018), while high expression of PRUNE2 protein correlates with favorable prognosis in neuroblastoma (Machida et al., 2006). The gene discussed is PRUNE2; the disease is malignant tumor of parathyroid gland.